Tristan Edwards and the business of getting ideas off the ground

In Tristan Edwards’s office, the Wright brothers had a job to do. A photograph of their 1903 flight hung on the wall at Life Biosciences. Edwards described it in a 2019 interview as a reminder of what the company was attempting. An investor who had spent years studying markets had chosen an image of something leaving the ground.

There is something pleasingly uncorporate about that choice. An aircraft assembled by two bicycle makers offers rather more narrative possibility than a framed mission statement. It also introduces a problem that runs through Edwards’s career: an idea can be persuasive long before anyone has built the organisation capable of carrying it.

Edwards had co-founded Life Biosciences with David Sinclair in 2017 and served as its first chief executive. Before that came an international investment career. Afterward came further company building, including Entheos Labs and the Australian incubator Proto Axiom. His working life connects the people who produce ideas with the capital, colleagues and institutions needed to develop them. The photograph makes a useful place to begin.

“We have the photo of this on our office wall, to remind us of who we are.”

Tristan Edwards, 2019, on the Wright brothers’ first flight

The apprenticeship before the departure

His early professional world had its own rules about evidence. Edwards studied commerce at the University of Tasmania and began as an analyst with the Australian Commonwealth Department of Finance. His subsequent investment roles included Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. The geography extended across Australia, London, Hong Kong and Singapore.

Those names describe a different education from the one usually associated with a research company’s founder. Edwards’s experience covered financial capital markets, regulatory compliance and fiduciary oversight. His company biographies also record that he held the CFA, CMT and CPA designations. Numbers, obligations and the handling of other people’s money came before the business of building research ventures.

At Mosaic, he served as chief investment officer and chairman from January 2012 to October 2014. In 2015, he consulted for private equity and venture capital groups, including BlueSky in Australia. That sequence puts a useful intermediate step between the trading career and Life Biosciences: he was already working with the financing of private businesses.

The move into founding changed his relationship with an investment. A portfolio manager can decide whether to own a position. A founder also has to decide who will run the organisation, how its parts will cooperate and which tasks deserve scarce money. Edwards brought the financial apprenticeship with him. The work acquired more moving parts.

Building the business around the work

At Life Biosciences, Edwards and Sinclair assembled a family of companies. The early structure gave individual teams room to pursue their own work while sharing resources supplied by the parent. By early 2019, the business described six daughter companies operating both independently and together. Even its vocabulary made the organisation sound less like a single startup than a slightly complicated household.

The shared provisions were substantial. They included experienced management, communications and data infrastructure, and a 24,000-square-foot research facility in Cambridge, Massachusetts. The practical question was how to give separate teams access to resources that would be expensive to assemble one company at a time.

This is where Edwards’s career becomes more interesting than a simple change of industry. He was helping design the container for other people’s expertise. Sinclair brought his academic background; Edwards brought experience with capital and business organisation. The partnership placed those capabilities inside the same enterprise, with smaller companies able to draw on the surrounding structure.

There was a financial test, too. In January 2019, Life Biosciences announced a $50 million Series B financing. It had initially aimed for $25 million and increased the round to accommodate investor demand. The participating investors included individuals, family trusts and other professional investors. The company had persuaded a varied group of backers to finance its next stage.

A larger round is a concrete achievement, but it also increases the work ahead. More money supports more commitments: teams, space, equipment and decisions about what happens next. In Edwards’s case, the financing story sits beside the organisational story. Raising capital and constructing something capable of using it were parts of the same assignment.

The early model also gave his investment experience a visible form. Instead of treating each team as an entirely separate business with entirely separate overheads, the parent supplied resources across the group. That arrangement made coordination part of the founding task. Independence had to coexist with shared facilities and management. The company structure was itself a decision about how to deploy capital.

The founder changes seats

Then came a change in the executive chair. In March 2019, Life Biosciences announced Mehmood Khan as its incoming chief executive. Khan had been vice chairman and chief scientific officer at PepsiCo and had previously led global research and development at Takeda. Edwards remained president and took the chief investment officer role.

The change matters because the title “former CEO” can flatten a career into a departure. Here, the announcement described a redistribution of responsibilities. The founding executive continued in the business, with investment explicitly part of his brief. Khan brought experience from larger organisations. Edwards’s place in the company moved closer to the financial expertise he had developed before founding it.

His public response was welcoming. He praised the business and scientific experience Khan would bring and described him as the right leader for the company’s next stage. There is no need to invent a private drama around the succession. The visible fact is an early founder making room for another executive while retaining a defined responsibility.

In April that year, Edwards also joined the board of Alterity Therapeutics, alongside Sinclair, following Life Biosciences’ investment. His working responsibilities now included public-company governance as well as the private-company network. The investor who had become a founder was also taking a seat where oversight, reporting and shareholder obligations were part of the job.

The Australian question

Australia remained part of the story. In 2021, Edwards and Anthony Liveris co-founded Proto Axiom, a business intended to support early ventures emerging from research. The problem they addressed was specific: Australian institutions could generate intellectual property, while the capabilities and backing needed to develop it commercially were harder to assemble at home.

By October 2022, when Proto Axiom announced its initial fundraising, Edwards was speaking publicly about retaining more of the commercial benefit from Australian research. His emphasis fell on developing capability within the country and bringing expertise and early capital to universities. The ambition concerned where companies could be built, as much as which projects could receive a cheque.

That distinction has practical consequences. Technical oversight, administrative support, later financing and hands-on assistance all featured in Proto Axiom’s account of its model. An academic team could need several of these at once. Money arrives as a number; the work of putting it to use arrives as a crowded calendar.

In August 2024, Proto Axiom reported a $20 million first close toward a planned $30 million Series B. The wording deserves care: the first close and the full target were different figures. For Edwards’s story, the round marks the continuation of an approach he had used before, combining investment with the construction of a supporting business environment.

The link back to Australia also gives this chapter a particular geography. Edwards’s earlier career had taken him into several overseas financial centres. Proto Axiom directed overseas and domestic backing toward Australian ventures. In that sense, his international connections became relevant to a local question: how much of the work after a discovery could remain close to the institutions that produced it?

More than one seat at the table

Today, Entheos Labs lists Edwards as its chief executive, and Life Biosciences identifies him as an Entheos co-founder as well as its own co-founder. Proto Axiom’s current team page lists him as a non-executive director. Those titles describe different kinds of involvement: running one enterprise, remaining a founder of another, and providing board oversight at a third.

The distinctions help explain the breadth of his work without turning every affiliation into the same job. A chief executive carries operating responsibility. A non-executive director contributes through governance. A co-founder’s connection survives later changes in management. Edwards’s record contains all three, at different points and sometimes at the same time.

Proto Axiom also credits him with co-founding J-Foods and other university spinouts. The recurring setting is the boundary between institutional research and a business with its own responsibilities. His career has repeatedly taken him to that boundary, carrying experience from markets into organisations whose work requires a different sort of patience.

The Wright brothers’ photograph belongs here, too. Edwards chose an example in which a demonstration changed what people were prepared to believe. His own contribution has largely concerned the arrangements around an attempt: who joins, how it is financed, what can be shared and when leadership should change. The picture on the wall supplied the romance. The organisation underneath it required rather more paperwork.